| rsID
|
Gene
|
Variant
|
REF/ALT
|
Effect of ALT
|
i-id (23andMe)
|
On chip?
|
| rs1799752
|
ACE
|
Alu I/D, intron 16
|
D/I
|
DD show greater BP drop on ACEI (enalapril or lisinopril) than DI or II; II show greater drop on ARB (irbesartan) than DI or DD
|
|
|
| rs1799998
|
CYP11B2
|
|
T/C
|
Preliminary studies: TT shows greater BP drop on irbesartan; CC shows greater drop on candesartan
|
|
23andMe v4, Ancestry v2, 23andMe v5, Ancestry v2c, 23andMe v3, FTDNA2, HumanOmni1Quad, Illumina Human 1M, Ancestry v2d
|
| rs1799853
|
CYP2C9
|
CYP2C9*2; C430T
|
C/T
|
CYP2C9*2 carriers respond better to irbesartan than non-carriers
|
|
23andMe v4, 23andMe v5, Ancestry v2c, 23andMe v3, HumanOmni1Quad, 23andMe v1, 23andMe v2, Ancestry v2d
|
| rs699
|
AGT
|
M235T
|
T/C
|
Mixed results re both efficacy and safety
|
|
23andMe v4, Ancestry v2, 23andMe v5, Ancestry v2c, 23andMe v3, FTDNA2, HumanOmni1Quad, 23andMe v1, 23andMe v2, Illumina Human 1M, Ancestry v2d
|
| rs4329
|
ACE
|
|
G/A
|
ACEI therapy may be more effective in (A;A) individuals compared to (A;G) and (G;G)
|
|
23andMe v4, Ancestry v2, 23andMe v5, Ancestry v2c, 23andMe v3, Affy GenomeWide 6, FTDNA2, HumanOmni1Quad, 23andMe v1, 23andMe v2, Illumina Human 1M, Ancestry v2d
|
| rs4149056
|
SLCO1B1
|
T521C; Val174Ala
|
T/C
|
C allele carriers more likely to have enalapril-induced cough
|
|
23andMe v4, Ancestry v2, 23andMe v5, Ancestry v2c, 23andMe v3, Affy GenomeWide 6, HumanOmni1Quad, 23andMe v1, 23andMe v2, Illumina Human 1M, Ancestry v2d
|
| rs8016905
|
BDKRB2
|
intron 2 variant
|
G/A
|
(A;G) heterozygotes ~2x more likely to experience ACEI-induced cough than (A;A) or (G;G) genotypes
|
|
FamilyTreeDNA, 23andMe v4, Ancestry v2, 23andMe v5, Ancestry v2c, 23andMe v3, Affy GenomeWide 6, FTDNA2, HumanOmni1Quad, 23andMe v1, 23andMe v2, Illumina Human 1M, Ancestry v2d
|
| rs495828
|
ABO
|
|
G/T
|
GG individuals likely to show greater BP drop on ACEI drugs than GT & TT
|
|
23andMe v4, Ancestry v2, 23andMe v5, Ancestry v2c, 23andMe v3, 23andMe v2, Illumina Human 1M, Ancestry v2d
|
| rs500766
|
PRKCQ
|
|
C/T
|
T carriers are at lower risk of ACEI-associated angioedema
|
|
NatGeo2, FamilyTreeDNA, 23andMe v4, Ancestry v2, 23andMe v5, Ancestry v2c, 23andMe v3, Affy GenomeWide 6, FTDNA2, HumanOmni1Quad, 23andMe v1, 23andMe v2, Illumina Human 1M, Ancestry v2d
|
| rs2724635
|
ETV6
|
|
T/C
|
CC individuals at 2-3x higher risk for ACEI-associated angioedema
|
|
NatGeo2, 23andMe v4, 23andMe v3, Affy GenomeWide 6, 23andMe v1, 23andMe v2, Illumina Human 1M
|
| rs989692
|
MME
|
|
C/T
|
TT individuals at higher risk than CC or CT for ACEI-associated angioedema in African-Americans
|
|
23andMe v4, Ancestry v2, Ancestry v2c, 23andMe v3, FTDNA2, HumanOmni1Quad, 23andMe v1, 23andMe v2, Illumina Human 1M, Ancestry v2d
|
| rs3788853
|
XPNPEP2
|
C2399A
|
G/T
|
Men who carry a T allele are at ~2x higher risk for ACEI-induced angioedema (but not women)
|
|
23andMe v4, Ancestry v2, 23andMe v5, Ancestry v2c, 23andMe v3, Affy GenomeWide 6, HumanOmni1Quad, 23andMe v2, Ancestry v2d
|
| rs12750834
|
REN
|
C-5312T
|
G/A
|
GG individuals show a greater drop in BP on ARBs (valsartan) compared to A carriers
|
|
23andMe v5
|
]):
